Therapeutic Solutions International Announces Licensing of Additional Technologies to Pan American Cancer Treatment Center
June 06 2018 - 9:00AM
InvestorsHub NewsWire
Therapeutic Solutions
International Announces Licensing of Additional Technologies to
Pan American Cancer Treatment Center
OCEANSIDE, CA -- June 05, 2018 -- InvestorsHub
NewsWire -- Therapeutics Solutions International, Inc., (OTC
Markets: TSOI) announced today their plans to license Pan Am
four additional immunotherapy products developed by the
Company.
The immune system's natural capacity to detect and
destroy abnormal cells may prevent the development of many cancers.
However, cancer cells are sometimes able to avoid detection and
destruction by the immune system. Cancer cells
may:
- reduce the expression of tumor antigens on their
surface, making it harder for the immune system to detect
them
- express proteins on their surface that induce
immune cell inactivation
- induce cells in the surrounding environment
(microenvironment) to release substances that suppress immune
responses and promote tumor cell proliferation and
survival
In the past few years,
the rapidly advancing field of cancer immunology has produced
several new methods of treating cancer, called immunotherapies,
which increase the strength of immune responses against tumors.
Immunotherapies either stimulate the activities of specific
components of the immune system or counteract signals produced by
cancer cells that suppress immune responses.
These advances in cancer immunotherapy are the result of long-term
investments in basic research on the immune system research that
continues today by scientists at TSOI.
"The licensing of these additional patent-pending
technologies to Pan Am, which includes Cancer Metabolic Detox,
innaMune, LymphoBoost, and MemoryMune, are critical components to
our overall cancer platform developed in-house by Company
scientists. This will give new tools to the physicians at Pan Am to
combat different cancers at different levels, along with the
administration of StemVacs, our immunotherapy platform" said
Timothy Dixon, President, and CEO of Therapeutic Solutions
International. "Although we recently announced the licensing of our
StemVacs platform to Pan Am to treat stages 1-4 in both prostate
and breast cancer, these additional therapies will allow for
additional protocols to treat additional cancers such as kidney,
liver, lung, and melanoma" added Mr. Dixon.
The following products can be used together to
attack cancer at different levels, as well as to be used alone or
in combination with existing therapies.
Cancer Metabolic DeTox:
By administering Cancer Metabolic DeTox, the innate arm of the
immune system has a chance to regenerate. This positions the
patient for a better outcome after administration of specific
immune stimulating vaccines.
innaMune: Is a biological product derived
from a tissue culture of blood cells derived from healthy donors.
It is a combination of cytokines that maintain activity of innate
immune system cells, as well as having the ability to shift M2
macrophages to M1.
LymphoBoost: Is a proprietary formulation
of Mifepristone, a drug approved for another indication, which we
have shown to be capable of stimulating lymphocytes, particularly
NK cells and T cells, both critical in maintaining anti-tumor
immunity.
MemoryMune: Is a product derived from a
two-step culture process of donor blood cells. The product
MemoryMune reawakens dormant immune memory cells. It is known that
many cancer patients possess memory T cells that enter the tumor,
however, once inside the tumor these cells are inactivated.
MemoryMune contains a unique combination of growth factors specific
for immune system cells called "cytokines".
The overarching approach to cancer on our StemVacs
platform is as follows:
- Treat innate immune suppression: Administration of
oral apigenin/pterostilbene (Cancer Metabolic DeTox
Product) to decrease immune suppressive toxic molecules made
by tumor and tumor microenvironment.
- Treat adaptive immune suppression: Administration
of MemoryMune to activate dormant memory cells recognizing the
tumor. Administration of LymphoBoost to repair deficient IL-12
production.
- Stimulation of immune response to cancer stem
cells (StemVacs).
- Consolidation and maintenance of immunity: Cycles
of StemVacs, supported by innaMune and
LymphoBoost
"At the Pan Am Cancer Treatment Centers, we are
committed to providing a multi-disciplinary attack on cancer
through concurrently activating multiple arms of the immune system.
By working with scientists at TSOI, we are excited to offer to our
patients a new spectrum of therapeutic approaches, thus positioning
us uniquely amongst cancer immunotherapy" said Dr. Javier Lopez,
Chief Executive Officer of the Pan American Cancer Treatment
Center. "By combining second generation cellular therapeutics, such
as antigen-pulsed dendritic cells, together with natural immune
stimulants, we are confident in our ability to provide second to
none immunotherapeutic protocols".
About Therapeutic Solutions International,
Inc.
Therapeutic Solutions International is focused on immune modulation
for the treatment of several specific diseases. Immune modulation
refers to the ability to upregulate (make more active) or
downregulate (make less active) one's immune system. The Company's
corporate website is www.therapeuticsolutionsint.com
and e-commerce at www.youcanordernow.com.
About Pan Am Cancer
Treatment Center
Pan Am Cancer Treatment Center contact information:
Telephone: (619) 735-9581
Diego Rivera #2339 suite 108
Zona Rio, Tijuana B.C. 22010
www.cancerimmunotherapy.mx
info@cancerimmunotherapy.mx
Safe Harbor Statement
This release contains forward-looking statements
that are based upon current expectations or beliefs, as well as a
number of assumptions about future events. Although we believe that
the expectations reflected in the forward-looking statements and
the assumptions upon which they are based are reasonable, we can
give no assurance that such expectations and assumptions will prove
to have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. The reader is cautioned not
to put undue reliance on these forward-looking statements, as these
statements are subject to numerous risk factors as set forth in our
SEC filings. To the extent that statements in this press release
are not strictly historical, including statements as to product
launch timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT
INFORMATION
Therapeutic Solutions International, Inc.
ir@tsoimail.com
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Apr 2024 to May 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From May 2023 to May 2024